Bitdeer Technologies Group vs State Street SPDR S&P Biotech ETF — how do they compare? Bitdeer Technologies Group trades at $9.21 (market cap $2.36B), while State Street SPDR S&P Biotech ETF trades at $159.22. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Bitdeer Technologies Group nearer its low. Which is the better fit depends on your goals.
| BTDR | XBI | |
|---|---|---|
Market Cap | $2.36B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $25.90 | $164.28 |
52-Week Low | $7.28 | $86.92 |
Enterprise Value | $3.85B | — |
Signals from Pluang's Aura AI — not financial advice
BTDR trades at $9.18, up 5.58% today but facing bearish technical signals with 13 of 13 moving averages indicating sell signals. The company reported Q2 2026 revenue growth but missed EPS expectations for the fourth consecutive quarter with a loss of $0.37 per share. Recent developments include a significant $4.7 billion AI data center deal announced August 4, 2026, signaling strategic expansion beyond Bitcoin mining into AI infrastructure.
Despite analyst optimism with 82% buy ratings and a $22.43 consensus price target, fundamental challenges persist including negative net income margin (-28.14%) and cash flow concerns. The stock offers substantial upside potential if AI initiatives succeed but faces execution risk amid volatile cryptocurrency markets and competitive pressures in the infrastructure sector.
XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.
The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.
Trailing returns across standard periods
Latest headlines on both assets
Bitdeer is a world-leading technology company for blockchain and high-performance computing. It provides comprehensive digital asset mining solutions, including cloud mining, hosting, and data center management.
Read more on BTDR →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →